阅读说明：本技术 一种包含绿原酸的组合物及其在延缓衰老方面的应用 (Chlorogenic acid-containing composition and application thereof in delaying senescence ) 是由 徐美利 连运河 程鑫颖 牛志平 田洪 柴燃 于 2021-09-28 设计创作，主要内容包括：本发明涉及一种组合物,尤其涉及一种包含绿原酸的组合物及其在延缓衰老方面的应用。所述组合物包括：绿原酸；以组合物的总质量为基准,所述绿原酸的占比为50～70wt.％；所述组合物还包括：糖苷类化合物和黄酮；其中,所述糖苷类化合物与所述绿原酸的质量比为(2～4)：(5～7)；所述黄酮与所述绿原酸的质量比为(1～3)：(5～7)。本发明提供的组合物在应用过程中,可增加肠道中疣微菌门的丰度,同时降低肠道中变形菌门的丰度,最终达到延缓衰老的作用。(The invention relates to a composition, in particular to a composition containing chlorogenic acid and application thereof in delaying senescence. The composition comprises: chlorogenic acid; the chlorogenic acid accounts for 50-70 wt% of the total mass of the composition; the composition further comprises: glycosides and flavones; wherein the mass ratio of the glucoside compound to the chlorogenic acid is (2-4): (5-7); the mass ratio of the flavone to the chlorogenic acid is (1-3): (5-7). In the application process of the composition provided by the invention, the abundance of verrucomicrobia in intestinal tracts can be increased, and meanwhile, the abundance of proteobacteria in intestinal tracts is reduced, so that the effect of delaying senescence is finally achieved.)

1. A composition characterized in that it comprises: chlorogenic acid; the chlorogenic acid accounts for 50-70 wt% of the total mass of the composition;

the composition further comprises: glycosides and flavones;

wherein the mass ratio of the glucoside compound to the chlorogenic acid is (2-4): (5-7); the mass ratio of the flavone to the chlorogenic acid is (1-3): (5-7).

2. The composition according to claim 1, wherein the chlorogenic acid is present in an amount of 50-65 wt.%, based on the total mass of the composition;

and/or the mass ratio of the glucoside compound to the chlorogenic acid is (2.0-3.5): (5.0-6.5); the mass ratio of the flavone to the chlorogenic acid is (1.2-2.8): (5.0-6.5).

3. The composition of claim 2, wherein the chlorogenic acid is present in an amount of 55 to 65 wt.%, based on the total mass of the composition;

and/or the mass ratio of the glucoside compound to the chlorogenic acid is (2.0-3.0): (5.5-6.5); the mass ratio of the flavone to the chlorogenic acid is (1.4-2.6): (5.5-6.5).

4. The composition according to claim 1, characterized in that it comprises the following components in parts by weight: 50-70 parts of chlorogenic acid, 20-40 parts of glucoside compounds and 10-30 parts of flavone;

preferably, the composition comprises the following components in parts by weight: 50-65 parts of chlorogenic acid, 20-35 parts of glucoside compounds and 12-28 parts of flavone;

more preferably, the composition comprises the following components in parts by weight: 55-65 parts of chlorogenic acid, 20-30 parts of glucoside compounds and 14-26 parts of flavone.

5. The composition of claim 4, wherein the parent nucleus of the glycoside compound is lignan; the structural formula of the lignan is shown as a formula I:

and/or, the mother nucleus of the flavone is flavanol; the structural formula of the flavanol is shown in a formula II:

6. use of the composition according to any one of claims 1 to 5 for the preparation of a food additive, food or pharmaceutical product, wherein the food additive, food or pharmaceutical product has an anti-aging effect.

7. The use according to claim 6, wherein the food additive, food or pharmaceutical product is used to increase the abundance of Oomycota wartii and decrease the abundance of Proteobacteria.

8. A food product comprising a composition as claimed in any one of claims 1 to 5 and auxiliary ingredients acceptable in food products.

9. A pharmaceutical product comprising the composition of any one of claims 1 to 5 and pharmaceutically acceptable auxiliary ingredients thereof.

10. A food additive characterized by comprising the composition according to any one of claims 1 to 5.

Technical Field

The invention relates to a composition, in particular to a composition containing chlorogenic acid and application thereof in delaying senescence.

Background

Intestinal microbiota is becoming a key regulator of a variety of metabolic, immune, and neuroendocrine pathways; the dysbiosis of intestinal microbiota is related to main diseases such as obesity, type 2 diabetes, cardiovascular diseases, nonalcoholic fatty acid liver diseases and cancer.

In 2019, a relation between aging and intestinal microbiota was found by scientists at Ouyveroni university in Spain in Nature Medicine; the research shows that the two different presenility mouse models have the characteristic of intestinal canal imbalance, wherein the abundance of proteobacteria and cyanobacteria is increased, and the abundance of verrucomicrobia is reduced; researchers also find that human presenility patients also show intestinal disorder, and the longlived human intestinal tract has high abundance of bacteria of the phylum verrucomicrobia and low abundance of proteus; the healthy life can be prolonged by transplanting wild mouse fecal flora into two presenility type mouse models, and the simple transplantation of bacteria of the phylum of Microbactera wartae also has the effect of prolonging the life (Nature Medicine,25, 1234-.

Based on the research, the abundance of the verrucomicrobia in the intestinal tract is increased, the abundance of the proteobacteria is reduced, and the effect of delaying senescence can be achieved.

In view of this, the invention is particularly proposed.

Disclosure of Invention

The invention aims to provide a composition which can increase the abundance of verrucomicrobia in intestinal tracts, reduce the abundance of proteobacteria and finally achieve the effect of delaying senility; another object of the present invention is to provide the use of the composition for delaying aging.

Specifically, the invention provides the following technical scheme:

the present invention provides a composition comprising: chlorogenic acid; the chlorogenic acid accounts for 50-70 wt% of the total mass of the composition;

the composition further comprises: glycosides and flavones;

wherein the mass ratio of the glucoside compound to the chlorogenic acid is (2-4): (5-7); the mass ratio of the flavone to the chlorogenic acid is (1-3): (5-7).

The invention aims at delaying senility, tries a large number of components and a compounding mode of the components, and finds that a composition obtained by further adding glycoside compounds and flavone by taking chlorogenic acid as a main body can effectively increase the abundance of verrucomicrobia in intestinal tracts and effectively reduce the abundance of proteobacteria in intestinal tracts in the research and development process, thereby achieving the aim of delaying senility.

Further, the content of chlorogenic acid in the composition is controlled within the range of 50-70 wt.%, and the mass ratio of the glycoside compounds to the chlorogenic acid is controlled within the range of (2-4): (5-7), the mass ratio of the flavone to the chlorogenic acid is controlled to be (1-3): (5-7), the abundance of verrucomicrobia in the intestinal tract can be increased, and the abundance of proteobacteria in the intestinal tract can be reduced.

In order to further increase the abundance of verrucomicrobia in the intestinal tract, reduce the abundance of proteobacteria in the intestinal tract and further increase the effect of delaying senescence of the composition, the invention optimizes the mixture ratio of the components, and concretely comprises the following steps:

preferably, the chlorogenic acid accounts for 50-65 wt% of the total mass of the composition;

further, the mass ratio of the glycoside compounds to the chlorogenic acid is (2.0-3.5): (5.0-6.5); the mass ratio of the flavone to the chlorogenic acid is (1.2-2.8): (5.0-6.5).

The invention also discovers that the content of the chlorogenic acid in the composition is controlled within the range of 50-65 wt.%, and the mass ratio of the glucoside compounds to the chlorogenic acid is controlled within the range of (2.0-3.5): (5.0-6.5), the mass ratio of flavone to chlorogenic acid is controlled to be (1.2-2.8): (5.0-6.5), the abundance of verrucomicrobia in intestinal tracts can be further increased, and the abundance of proteobacteria in intestinal tracts can be reduced, so that the effect of the composition on delaying senescence is improved.

In order to better control the raw material cost, the percentage of the chlorogenic acid in the composition can be controlled to be 55-65 wt.%; the addition of chlorogenic acid in the dosage range can also obtain the composition with good effect of delaying aging, and the raw material cost is reduced.

Namely: the chlorogenic acid accounts for 55-65 wt% of the total mass of the composition; in this case, the mass ratio of the glycoside compound to the chlorogenic acid is (2.0-3.0): (5.5-6.5); the mass ratio of the flavone to the chlorogenic acid is (1.4-2.6): (5.5-6.5).

Preferably, the composition comprises the following components in parts by weight: 50-70 parts of chlorogenic acid, 20-40 parts of glucoside compounds and 10-30 parts of flavone.

Further, the composition comprises the following components in parts by weight: 50-65 parts of chlorogenic acid, 20-35 parts of glucoside compounds and 12-28 parts of flavone.

Still further, the composition comprises the following components in parts by weight: 55-65 parts of chlorogenic acid, 20-30 parts of glucoside compounds and 14-26 parts of flavone.

Preferably, the parent nucleus of the glycoside compound is lignan; the structural formula of the lignan is shown as a formula I:

preferably, the parent nucleus of the flavone is flavanol; the structural formula of the flavanol is shown in a formula II:

therefore, the invention provides a brand new composition, and in the application process of the composition, the abundance of verrucomicrobia in intestinal tracts can be increased, and meanwhile, the abundance of proteobacteria in intestinal tracts is reduced, so that the effect of delaying senescence is finally achieved.

The invention also provides the application of the composition in delaying senility.

The invention also provides application of the composition in preparing food additives, foods or medicines, wherein the food additives, foods or medicines have the effect of delaying senescence.

Preferably, the food additive, food or pharmaceutical product is used to increase the abundance of the phylum verrucomicrobia (in the intestine) and decrease the abundance of the phylum proteobacteria (in the intestine).

The invention also provides a food which contains the composition and auxiliary components acceptable in the food.

The invention also provides a medicine which contains the composition and pharmaceutically acceptable auxiliary components thereof.

The invention also provides a food additive which contains the composition.

The invention has the beneficial effects that:

in the application process of the composition provided by the invention, the abundance of verrucomicrobia in intestinal tracts can be increased, and meanwhile, the abundance of proteobacteria in intestinal tracts is reduced, so that the effect of delaying senescence is finally achieved.

Drawings

FIG. 1 is a schematic representation of the survival rate of mice;

fig. 2 is a graph showing the relative abundance of Top5 bacteria at the phylum level of intestinal contents.

Detailed Description

The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.

In order to facilitate comparison of the effects, chlorogenic acid mentioned in the following examples is conventional stevia chlorogenic acid purchased from a commercial market, and the effects of the present invention can be achieved as long as the components used are within the range defined in the summary of the invention when the specific implementation is performed.

The examples do not show the specific techniques or conditions, according to the technical or conditions described in the literature in the field, or according to the product specifications. The reagents or instruments used are conventional products available from regular distributors, not indicated by the manufacturer.

Example 1

The embodiment provides a composition, which consists of the following components in parts by weight: 60 parts of chlorogenic acid, 25 parts of glucoside compounds and 20 parts of flavone.

Example 2

The embodiment provides a composition, which consists of the following components in parts by weight: 50 parts of chlorogenic acid, 20 parts of glucoside compounds and 30 parts of flavone.

Example 3

The embodiment provides a composition, which consists of the following components in parts by weight: 70 parts of chlorogenic acid, 20 parts of glucoside compounds and 10 parts of flavone.

Comparative example 1

The comparative example provides a composition consisting of the following components in parts by weight: 20 parts of chlorogenic acid, 60 parts of glucoside compounds and 10 parts of flavone.

Experimental example 1

The effects of the present invention will be described below by experimental data (experimental drugs are the compositions of examples 1 to 3 of the present invention and comparative example 1).

1. Materials and reagents

And (3) testing a sample: the compositions of examples 1-3 and comparative example 1 were stored in a sealed and dark state at room temperature;

experimental animals: geriatric (19 months old) SPF grade C57BL/6J mice, male, purchased from sbefort (beijing) biotechnology limited;

maintenance feed and bedding materials were purchased from sbefu (beijing) biotechnology limited.

2. Test device and instrument

An electronic balance, an ultra-clean workbench, an ultraviolet spectrophotometer, an ultra-low temperature refrigerator at-80 ℃, surgical scissors, ophthalmological tweezers, a microscope, a high-pressure steam sterilization pot and the like.

3. Mouse grouping and dose design

After adaptive feeding for 3 days, 150 aged mice were randomly divided into 5 treatment groups by body weight, 3 replicates of each treatment group, and 10 mice were each replicated, and were freely fed to the blank control group, the composition group of example 1, the composition group of example 2, the composition group of example 3, and the composition group of comparative example 1. And each cage is randomly placed according to the drawing principle, so that the influence of the growth environment on the test result is avoided.

4. Feed preparation

The purchased mouse maintenance feed (purchased from sbefu (beijing) biotechnology limited) was pulverized, and the composition of example 1, the composition of example 2, the composition of example 3, and the composition of comparative example 1 were added to the feed, and the mixture was uniformly mixed in a pulverizer, and 20% pure water was added, and the mixture was uniformly mixed and granulated in a granulator, and dried in an oven at 60 ℃ for 5 hours, and weighed after cooling. The blank control group was prepared by adding water only, and the other operations were the same.

5. Test method

After the adaptation period of the mice is over, the corresponding groups of feed are respectively given according to groups, the mice are fed for 22 weeks, the survival rate of each component is counted every week, and after the experiment is over, the intestinal flora detection of each group of mice is carried out.

6. Detection of intestinal flora

Sequencing intestinal content 16S rDNA: and (3) placing the intestinal contents of the mice in a test tube, and performing high-throughput sequencing to obtain intestinal flora differences of the mice.

7. Results

7.1 survival rate

When the stock quantity and the survival rate of the mice are analyzed, as shown in fig. 1, the experimental effect of the composition groups of examples 1-3 is obviously better than that of the blank control group and the composition group of comparative example 1, wherein the effect of the composition group of example 1 is optimal, and no death of the mice occurs for 7 weeks.

7.2 intestinal flora

Intestinal flora sequencing was performed on the blank control group, the composition group of example 1, and the blank control group according to the experimental protocol, and the results are shown in fig. 2 (a is the blank control group, B is the composition group of example 1, and C is the composition of comparative example 1); as can be seen from fig. 2, the level of the phylum verrucomicrobia in the composition group of example 1 was significantly increased as compared to the blank control group, and the level of the phylum verrucomicrobia in the composition group of comparative example 1 was increased.

7.3 analysis of differences between MRPP groups

The composition group of example 1 and the composition group of comparative example 1 were subjected to difference analysis between the MRPP groups, and the results are shown in table 1;

TABLE 1 analysis of differences between MRPP groups

Group	Value of A	P value
			Composition set of example 1	0.04831	0.021
Composition set of comparative example 1	0.0191	0.150

Note: a values between (-1, 1) and greater than 0 indicate significant differences between groups, less than 0 indicates greater intra-group differences than inter-group differences, and P < 0.05 indicates statistical significance.

As can be seen from table 1, the composition groups of example 1 differ significantly.

Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.